Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Coronary Artery Disease: HELP
Articles by Douglas J. Spriggs
Based on 2 articles published since 2008
||||

Between 2008 and 2019, Douglas J. Spriggs wrote the following 2 articles about Coronary Artery Disease.
 
+ Citations + Abstracts
1 Clinical Trial First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions With Very Small Reference Vessel Diameter. 2017

Price, Matthew J / Saito, Shigeru / Shlofmitz, Richard A / Spriggs, Douglas J / Attubato, Michael / McLaurin, Brent / Popma Almonacid, Alexandra / Brar, Sandeep / Liu, Minglei / Moe, Elizabeth / Mehran, Roxana. ·Department of Cardiovascular Diseases, Scripps Clinic, La Jolla, California. Electronic address: price.matthew@scrippshealth.org. · Shonan Kamakura General Hospital, Kamakura, Japan. · Saint Francis Hospital, Roslyn, New York. · Morton Plant Hospital, Clearwater, Florida. · NYU Langone Medical Center, New York, New York. · AnMed, Anderson, South Carolina. · Beth Israel Deaconess Medical Center, Cardiovascular Imaging Core Laboratory, Boston, Massachusetts. · Medtronic, Santa Rosa, California. · Department of Cardiology, Mount Sinai Medical Center, New York, New York. ·JACC Cardiovasc Interv · Pubmed #28728650.

ABSTRACT: OBJECTIVES: The aim of this study was to explore the safety and efficacy of a dedicated drug-eluting stent for the treatment of coronary lesions with very small reference vessel diameter (RVD). BACKGROUND: Smaller RVD is associated with increased risk for restenosis and target lesion failure (TLF) after stent implantation. METHODS: This was a prospective, single-arm, multicenter trial of the Resolute Onyx 2.0-mm zotarolimus-eluting stent. The primary endpoint was 12-month TLF, which was compared with a pre-specified performance goal. Subjects with stable or unstable angina or ischemia, target lesions ≤27 mm in length, and RVD ≥2.0 and <2.25 mm were eligible for enrollment. A subset of subjects underwent follow-up angiography at 13 months post-procedure. RESULTS: A total of 101 subjects with 104 lesions were enrolled. The mean age was 67.3 ± 9.6 years, 47% of subjects had diabetes, the mean lesion length was 12.6 ± 6.3 mm, and the mean RVD was 1.91 ± 0.26 mm. The rate of TLF at 12 months was 5.0%, fulfilling the pre-specified performance goal of 19% (p < 0.001). The rates of target lesion revascularization and target vessel myocardial infarction were 2.0% and 3.0%, respectively. There were no episodes of stent thrombosis. In-stent late lumen loss was 0.26 ± 0.48 mm, and the rate of binary restenosis was 12.0%. CONCLUSIONS: In this first report of a drug-eluting stent with a dedicated size to treat lesions with RVD <2.25 mm, the Resolute Onyx 2.0-mm zotarolimus-eluting stent was associated with a low rate of TLF and late lumen loss, without a signal for stent thrombosis. This novel-sized drug-eluting stent appears to be a feasible option for the treatment of coronary lesions in extremely small vessels. (Medtronic Resolute Onyx 2.0 mm Clinical Study; NCT02412501).

2 Clinical Trial Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial. 2011

Yeung, Alan C / Leon, Martin B / Jain, Ash / Tolleson, Thaddeus R / Spriggs, Douglas J / Mc Laurin, Brent T / Popma, Jeffrey J / Fitzgerald, Peter J / Cutlip, Donald E / Massaro, Joseph M / Mauri, Laura / Anonymous2980691. ·Stanford University School of Medicine, Palo Alto, California, USA. ·J Am Coll Cardiol · Pubmed #21470813.

ABSTRACT: OBJECTIVES: The RESOLUTE US (R-US) trial is a prospective, observational study designed to evaluate the clinical effectiveness of the Resolute zotarolimus-eluting stent (R-ZES) in a U.S. population. BACKGROUND: The R-ZES releases zotarolimus over a 6-month period in order to achieve optimal clinical effectiveness and safety. METHODS: The R-US trial recruited patients with de novo native coronary lesions suitable for 1- or 2-vessel treatment with stents from 2.25 to 4.0 mm in diameter. In the main analysis cohort (2.5- to 3.5-mm stents and single-lesion treatment), the primary endpoint was 12-month target lesion failure (TLF) defined as the composite of cardiac death, myocardial infarction (MI), and clinically-driven target lesion revascularization (TLR), compared with data from Endeavor zotarolimus-eluting stent (E-ZES) trials, adjusting for baseline covariates through propensity scores. RESULTS: Overall, 1,402 patients were enrolled with a mean reference vessel diameter of 2.59 ± 0.47 mm and diabetes prevalence of 34.4%. In the main analysis cohort, TLF was 3.7% at 12 months compared with historical E-ZES results (TLF = 6.5%). The R-ZES met the 3.3% margin of noninferiority (rate difference = -2.8%, upper 1-sided 95% confidence interval: -1.3%, p < 0.001). The overall TLF rate was 4.7%, and rates of cardiac death, MI, and TLR were 0.7%, 1.4%, and 2.8%, respectively. The 12-month rate of stent thrombosis was 0.1%. CONCLUSIONS: The R-ZES achieved a very low rate of clinical restenosis while maintaining low rates of important clinical safety events such as death, MI, and stent thrombosis at 1-year follow-up. (The Medtronic RESOLUTE US Clinical Trial [R-US]; NCT00726453).